PathAI, a leading AI-powered precision pathology company, has concluded a year marked by significant growth and advancements. The company developed and launched over 20 new AI products across oncology, MASH/MASLD and IBD; launched the AISight® image management system (IMS); distributed the AISight platform and IMS to a growing footprint of more than 50 labs globally; expanded clinical trial services to encompass MASH/MASLD, IBD and oncology; and honed its leadership team to drive biopharma business, regulatory strategy, and growth initiatives. Moreover, PathAI established key partnerships, presented new data at major industry conferences, and was recognized through several industry awards. The culmination of these 2023 achievements serves to further revolutionize the field of pathology, bringing more AI-driven tools to drug development and diagnostics.
Jan 15, 2024